Multiple Sclerosis: Early Treatment With Tecfidera And Tysabri Can Improve Outcomes

 
Published on April 26, 2017
Channel: Md Magazine
Source: Youtube

Kate Dawson, MD, VP, US Medical Biogen and team believes it’s imperative for patients diagnosed with multiple sclerosis (MS) to get treated early and be monitored during the course of the disease, because data continue to show that patients treated earlier and are switched appropriately do the best. “With respect to Tecfidera, we looked at a US claims database (of several years and over 5000 patients on Tecfidera) and compared it with patients who received teriflunomide. Results showed that Tecfidera was more beneficial,” Dawson told MD Magazine at AAN 2017.